Board of Directors approved the Company’s 2018 individual and consolidated financial statements

  1. Date of occurrence of the event: Mar 8, 2019
  2. Company name: OBI Pharma Inc.
  3. Relationship to the Company (please enter “head office” or subsidiaries”): Head office
  4. Reciprocal shareholding ratios: N/A
  5. Cause of occurrence:
    From the 2018 Individual/Consolidated Financial Statement:
    Individual Financial Statement:
    Operating loss :(1,300,667) thousand dollars
    Total comprehensive loss for the period :(1,224,428) thousand dollars
    Loss Per Share (in dollars) :( 7.06) dollars

    Consolidated Financial Statement:
    Operating loss :(1,427,683) thousand dollars
    Total comprehensive loss for the period :(1,251,780) thousand dollars
    Loss Per Share (in dollars) :( 7.06) dollars

  6. Countermeasures: N/A
  7. Any other matters that need to be specified: None